Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC reduced its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 67.0% during the 2nd quarter, Holdings Channel.com reports. The firm owned 23,026 shares of the company’s stock after selling 46,744 shares during the quarter. Squarepoint Ops LLC’s holdings in Amphastar Pharmaceuticals were worth $529,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Amphastar Pharmaceuticals by 192.8% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,262 shares of the company’s stock worth $29,000 after buying an additional 831 shares during the last quarter. Hantz Financial Services Inc. raised its position in Amphastar Pharmaceuticals by 3,430.8% during the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock valued at $32,000 after acquiring an additional 1,338 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Amphastar Pharmaceuticals by 62.2% in the second quarter. GAMMA Investing LLC now owns 2,162 shares of the company’s stock valued at $50,000 after acquiring an additional 829 shares during the period. IFP Advisors Inc boosted its position in Amphastar Pharmaceuticals by 75.7% in the 2nd quarter. IFP Advisors Inc now owns 2,035 shares of the company’s stock worth $52,000 after purchasing an additional 877 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 950.0% during the 1st quarter. Russell Investments Group Ltd. now owns 2,058 shares of the company’s stock worth $60,000 after purchasing an additional 1,862 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

AMPH opened at $26.29 on Thursday. The firm’s fifty day simple moving average is $25.80 and its two-hundred day simple moving average is $25.70. Amphastar Pharmaceuticals, Inc. has a 52-week low of $20.39 and a 52-week high of $39.01. The company has a market cap of $1.21 billion, a price-to-earnings ratio of 11.63, a PEG ratio of 7.41 and a beta of 0.91. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Thursday, November 6th. The company reported $0.93 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.10. The business had revenue of $191.84 million during the quarter, compared to analysts’ expectations of $186.90 million. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. Equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday. Zacks Research cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Needham & Company LLC lowered their target price on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Finally, Barclays started coverage on Amphastar Pharmaceuticals in a research report on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 target price on the stock. Two analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $31.00.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, Director Floyd F. Petersen sold 16,679 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $26.49, for a total value of $441,826.71. Following the completion of the transaction, the director directly owned 75,531 shares of the company’s stock, valued at approximately $2,000,816.19. This represents a 18.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard K. Prins sold 4,179 shares of the firm’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total value of $113,250.90. Following the completion of the transaction, the director owned 35,183 shares in the company, valued at $953,459.30. The trade was a 10.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 35,808 shares of company stock valued at $945,237 over the last quarter. 27.50% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.